

# Adrienne C Lahti

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5060341/publications.pdf>

Version: 2024-02-01

128  
papers

7,730  
citations

61984

43  
h-index

53230

85  
g-index

129  
all docs

129  
docs citations

129  
times ranked

8530  
citing authors

#	ARTICLE	IF	CITATIONS
1	Hippocampal Dysconnectivity and Altered Glutamatergic Modulation of the Default Mode Network: A Combined Resting-State Connectivity and Magnetic Resonance Spectroscopy Study in Schizophrenia. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2022, 7, 108-118.	1.5	10
2	The role of glutamate and GABA in cognitive dysfunction in schizophrenia and mood disorders – A systematic review of magnetic resonance spectroscopy studies. <i>Schizophrenia Research</i> , 2022, 249, 74-84.	2.0	50
3	Ultrastructural evidence for glutamatergic dysregulation in schizophrenia. <i>Schizophrenia Research</i> , 2022, 249, 4-15.	2.0	21
4	The neural substrates of neurological soft signs in schizophrenia: a systematic review. <i>NPJ Schizophrenia</i> , 2022, 8, .	3.6	4
5	White matter integrity, duration of untreated psychosis, and antipsychotic treatment response in medication-naïve first-episode psychosis patients. <i>Molecular Psychiatry</i> , 2021, 26, 5347-5356.	7.9	29
6	Neural Signatures of Memory Encoding in Schizophrenia Are Modulated by Antipsychotic Treatment. <i>Neuropsychobiology</i> , 2021, 80, 12-24.	1.9	5
7	Structural and Functional Default Mode Network Connectivity and Antipsychotic Treatment Response in Medication-Naïve First Episode Psychosis Patients. <i>Schizophrenia Bulletin Open</i> , 2021, 2, sgab032.	1.7	7
8	White Matter Neurometabolic Signatures Support the Deficit and Nondeficit Distinction in Antipsychotic-Naïve First-Episode Psychosis Patients. <i>Schizophrenia Bulletin</i> , 2021, 47, 1068-1076.	4.3	3
9	Neurite Orientation Dispersion and Density Imaging (NODDI) and duration of untreated psychosis in antipsychotic medication-naïve first episode psychosis patients. <i>NeuroImage Reports</i> , 2021, 1, 100005.	1.0	7
10	Neuroimaging as a Window Into the Pathophysiological Mechanisms of Schizophrenia. <i>Frontiers in Psychiatry</i> , 2021, 12, 613764.	2.6	10
11	Reinforcement learning abnormalities in the attenuated psychosis syndrome and first episode psychosis. <i>European Neuropsychopharmacology</i> , 2021, 47, 11-19.	0.7	7
12	Clinical Utility of Wearable Sensors and Patient-Reported Surveys in Patients With Schizophrenia: Noninterventional, Observational Study. <i>JMIR Mental Health</i> , 2021, 8, e26234.	3.3	6
13	Saliency network glutamate and brain connectivity in medication-naïve first episode patients – A multimodal magnetic resonance spectroscopy and resting state functional connectivity MRI study. <i>NeuroImage: Clinical</i> , 2021, 32, 102845.	2.7	14
14	Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggest Dentate Gyrus Pathology Linked to NMDA Receptor Hypofunction. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2021, 6, 1185-1192.	1.5	1
15	A multimodal neuroimaging study investigating resting-state connectivity, glutamate and GABA at 7 T in first-episode psychosis. <i>Journal of Psychiatry and Neuroscience</i> , 2021, 46, E702-E710.	2.4	10
16	Baseline Functional Connectivity Predicts Connectivity Changes Due to a Small Dose of Midazolam in Older Adults. <i>Anesthesia and Analgesia</i> , 2020, 130, 224-232.	2.2	5
17	Duration of Untreated Psychosis Correlates With Brain Connectivity and Morphology in Medication-Naïve Patients With First-Episode Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2020, 5, 231-238.	1.5	19
18	White matter and neurite morphology differ in psychogenic nonepileptic seizures. <i>Annals of Clinical and Translational Neurology</i> , 2020, 7, 1973-1984.	3.7	22

#	ARTICLE	IF	CITATIONS
19	A multimodal magnetoencephalography 7T fMRI and 7T proton MR spectroscopy study in first episode psychosis. <i>NPJ Schizophrenia</i> , 2020, 6, 23.	3.6	18
20	Hippocampal glutamate and hippocampus subfield volumes in antipsychotic-naïve first episode psychosis subjects and relationships to duration of untreated psychosis. <i>Translational Psychiatry</i> , 2020, 10, 137.	4.8	38
21	Aberrant static and dynamic functional patterns of frontoparietal control network in antipsychotic-naïve first episode psychosis subjects. <i>Human Brain Mapping</i> , 2020, 41, 2999-3008.	3.6	15
22	Proof of mechanism and target engagement of glutamatergic drugs for the treatment of schizophrenia: RCTs of pomaglumetad and TS-134 on ketamine-induced psychotic symptoms and pharmacobOLD in healthy volunteers. <i>Neuropsychopharmacology</i> , 2020, 45, 1842-1850.	5.4	32
23	A Prospective Longitudinal Investigation of Cortical Thickness and Gyrfication in Schizophrenia. <i>Canadian Journal of Psychiatry</i> , 2020, 65, 381-391.	1.9	22
24	Neurometabolic correlates of 6 and 16 weeks of treatment with risperidone in medication-naïve first-episode psychosis patients. <i>Translational Psychiatry</i> , 2020, 10, 15.	4.8	13
25	7T Proton Magnetic Resonance Spectroscopy of the Anterior Cingulate Cortex in First-Episode Schizophrenia. <i>Schizophrenia Bulletin</i> , 2019, 45, 180-189.	4.3	94
26	Cognitive control network dysconnectivity and response to antipsychotic treatment in schizophrenia. <i>Schizophrenia Research</i> , 2019, 204, 262-270.	2.0	21
27	Ketamine induced changes in regional cerebral blood flow, interregional connectivity patterns, and glutamate metabolism. <i>Journal of Psychiatric Research</i> , 2019, 117, 108-115.	3.1	17
28	Examining resting-state functional connectivity in first-episode schizophrenia with 7T fMRI and MEG. <i>NeuroImage: Clinical</i> , 2019, 24, 101959.	2.7	34
29	234. Hippocampal Glutamate and Resting State Functional Connectivity as Biomarkers of Treatment Response to Antipsychotic Medication. <i>Biological Psychiatry</i> , 2019, 85, S97.	1.3	0
30	117. Biomarker Assessment of Dose Dependent Target Engagement of mGluR-2,3 Partial Agonist for Schizophrenia Treatment. <i>Biological Psychiatry</i> , 2019, 85, S49.	1.3	0
31	A longitudinal neurite and free water imaging study in patients with a schizophrenia spectrum disorder. <i>Neuropsychopharmacology</i> , 2019, 44, 1932-1939.	5.4	37
32	A pilot study of combined endurance and resistance exercise rehabilitation for verbal memory and functional connectivity improvement in epilepsy. <i>Epilepsy and Behavior</i> , 2019, 96, 44-56.	1.7	21
33	Micro- and Macrostructural White Matter Integrity in Never-Treated and Currently Unmedicated Patients With Schizophrenia and Effects of Short-Term Antipsychotic Treatment. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 462-471.	1.5	15
34	A longitudinal magnetic resonance spectroscopy study investigating effects of risperidone in the anterior cingulate cortex and hippocampus in schizophrenia. <i>Schizophrenia Research</i> , 2019, 210, 239-244.	2.0	37
35	Relationship Between Cortical Excitation and Inhibition and Task-Induced Activation and Deactivation: A Combined Magnetic Resonance Spectroscopy and Functional Magnetic Resonance Imaging Study at 7T in First-Episode Psychosis. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2019, 4, 121-130.	1.5	27
36	Four-way multimodal fusion of 7T imaging data using an mCCA+jICA model in first episode schizophrenia. <i>Human Brain Mapping</i> , 2018, 39, 1475-1488.	3.6	24

#	ARTICLE	IF	CITATIONS
37	Mnemonic Discrimination Deficits in First-Episode Psychosis and a Ketamine Model Suggests Dentate Gyrus Pathology Linked to N-Methyl-D-Aspartate Receptor Hypofunction. <i>Biological Psychiatry: Cognitive Neuroscience and Neuroimaging</i> , 2018, 3, 231-238.	1.5	25
38	Paving the Way for Targeted Drug Development in Schizophrenia. <i>JAMA Psychiatry</i> , 2018, 75, 19.	11.0	2
39	Gyrification Connectomes in Unmedicated Patients With Schizophrenia and Following a Short Course of Antipsychotic Drug Treatment. <i>Frontiers in Psychiatry</i> , 2018, 9, 699.	2.6	19
40	A Longitudinal Multimodal Neuroimaging Study to Examine Relationships Between Resting State Glutamate and Task Related BOLD Response in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2018, 9, 632.	2.6	34
41	Digital Trajectories to Care in First-Episode Psychosis. <i>Psychiatric Services</i> , 2018, 69, 1259-1263.	2.0	31
42	Neurometabolic abnormalities in the associative striatum in antipsychotic-naïve first episode psychosis patients. <i>Psychiatry Research - Neuroimaging</i> , 2018, 281, 101-106.	1.8	12
43	Evaluation of fronto-striatal networks during cognitive control in unmedicated patients with schizophrenia and the effect of antipsychotic medication. <i>NPJ Schizophrenia</i> , 2018, 4, 8.	3.6	31
44	Brain structure, function, and neurochemistry in schizophrenia and bipolar disorder—a systematic review of the magnetic resonance neuroimaging literature. <i>NPJ Schizophrenia</i> , 2017, 3, 15.	3.6	164
45	Glutamate/glutamine concentrations in the dorsal anterior cingulate vary with Post-Traumatic Stress Disorder symptoms. <i>Journal of Psychiatric Research</i> , 2017, 91, 169-176.	3.1	20
46	The effect of saccadic eye movements on the sensor-level magnetoencephalogram. <i>Clinical Neurophysiology</i> , 2017, 128, 397-407.	1.5	5
47	325. Clinical Utility Study Towards the Use of Continuous Wearable Sensors and Patient Reported Surveys for Relapse Prediction in Patients at High Risk of Relapse in Schizophrenia. <i>Biological Psychiatry</i> , 2017, 81, S133.	1.3	2
48	631. Brain Structure, Function, and Neurochemistry across Schizophrenia and Bipolar Disorder – A Systematic Review of the Magnetic Resonance Neuroimaging Literature. <i>Biological Psychiatry</i> , 2017, 81, S255-S256.	1.3	0
49	Predictors of medication adherence and smoking cessation among smokers under community corrections supervision. <i>Addictive Behaviors</i> , 2017, 65, 111-117.	3.0	7
50	Risperidone Effects on Brain Dynamic Connectivity—A Prospective Resting-State fMRI Study in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2017, 8, 14.	2.6	40
51	Rapid Clozapine Titration in an Acutely Agitated Patient With Schizoaffective Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2016, 36, 276-277.	1.4	1
52	Change in brain network topology as a function of treatment response in schizophrenia: a longitudinal resting-state fMRI study using graph theory. <i>NPJ Schizophrenia</i> , 2016, 2, 16014.	3.6	100
53	Biochemistry of the cingulate cortex in autism: An MR spectroscopy study. <i>Autism Research</i> , 2016, 9, 643-657.	3.8	19
54	Abnormalities in large scale functional networks in unmedicated patients with schizophrenia and effects of risperidone. <i>NeuroImage: Clinical</i> , 2016, 10, 146-158.	2.7	94

#	ARTICLE	IF	CITATIONS
55	A combined diffusion tensor imaging and magnetic resonance spectroscopy study of patients with schizophrenia. <i>Schizophrenia Research</i> , 2016, 170, 341-350.	2.0	45
56	Aberrant Hippocampal Connectivity in Unmedicated Patients With Schizophrenia and Effects of Antipsychotic Medication: A Longitudinal Resting State Functional MRI Study. <i>Schizophrenia Bulletin</i> , 2016, 42, 1046-1055.	4.3	104
57	Making Progress Toward Individualized Medicine in the Treatment of Psychosis. <i>American Journal of Psychiatry</i> , 2016, 173, 5-7.	7.2	5
58	Contribution of substantia nigra glutamate to prediction error signals in schizophrenia: a combined magnetic resonance spectroscopy/functional imaging study. <i>NPJ Schizophrenia</i> , 2015, 1, 14001.	3.6	35
59	Effective connectivity during episodic memory retrieval in schizophrenia participants before and after antipsychotic medication. <i>Human Brain Mapping</i> , 2015, 36, 1442-1457.	3.6	72
60	SLC7A11 expression is associated with seizures and predicts poor survival in patients with malignant glioma. <i>Science Translational Medicine</i> , 2015, 7, 289ra86.	12.4	207
61	Cognitive risk profiles for anxiety disorders in a high-risk population. <i>Psychiatry Research</i> , 2015, 229, 572-576.	3.3	0
62	Multimodal neuroimaging based classification of autism spectrum disorder using anatomical, neurochemical, and white matter correlates. <i>Cortex</i> , 2015, 66, 46-59.	2.4	113
63	Race and Medication Adherence Moderate Cessation Outcomes in Criminal Justice Smokers. <i>American Journal of Preventive Medicine</i> , 2015, 49, 335-344.	3.0	33
64	Ventral Tegmental Area/Midbrain Functional Connectivity and Response to Antipsychotic Medication in Schizophrenia. <i>Neuropsychopharmacology</i> , 2014, 39, 1020-1030.	5.4	145
65	Open label smoking cessation with varenicline is associated with decreased glutamate levels and functional changes in anterior cingulate cortex: preliminary findings. <i>Frontiers in Pharmacology</i> , 2014, 5, 158.	3.5	19
66	Expectancies for the Effectiveness of Different Tobacco Interventions Account for Racial and Gender Differences in Motivation to Quit and Abstinence Self-Efficacy. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1174-1182.	2.6	12
67	Vergence eye movements in patients with schizophrenia. <i>Vision Research</i> , 2014, 102, 64-70.	1.4	12
68	How Low Should You Go? Determining the Optimal Cutoff for Exhaled Carbon Monoxide to Confirm Smoking Abstinence When Using Cotinine as Reference. <i>Nicotine and Tobacco Research</i> , 2014, 16, 1348-1355.	2.6	122
69	Basal ganglia volume in unmedicated patients with schizophrenia is associated with treatment response to antipsychotic medication. <i>Psychiatry Research - Neuroimaging</i> , 2014, 221, 6-12.	1.8	32
70	Delay discounting and task performance consistency in patients with schizophrenia. <i>Psychiatry Research</i> , 2014, 215, 286-293.	3.3	38
71	Hippocampalâ€”parietal dysconnectivity and glutamate abnormalities in unmedicated patients with schizophrenia. <i>Hippocampus</i> , 2014, 24, 1524-1532.	1.9	55
72	The Problem of Spurious Correlations Between Pairs of Brain Metabolite Values Measured in the Same Voxel With Magnetic Resonance Spectroscopyâ€”Reply. <i>JAMA Psychiatry</i> , 2014, 71, 339.	11.0	2

#	ARTICLE	IF	CITATIONS
73	Spatial and Temporal Mapping of De Novo Mutations in Schizophrenia to a Fetal Prefrontal Cortical Network. <i>Cell</i> , 2013, 154, 518-529.	28.9	507
74	Proton magnetic resonance spectroscopy of the substantia nigra in schizophrenia. <i>Schizophrenia Research</i> , 2013, 147, 348-354.	2.0	21
75	Magnetic Transfer Contrast Accurately Localizes Substantia Nigra Confirmed by Histology. <i>Biological Psychiatry</i> , 2013, 73, 289-294.	1.3	27
76	Increased Hippocampal Glutamate and Volumetric Deficits in Unmedicated Patients With Schizophrenia. <i>JAMA Psychiatry</i> , 2013, 70, 1294.	11.0	179
77	Memory Deficits in Schizophrenia: A Selective Review of Functional Magnetic Resonance Imaging (fMRI) Studies. <i>Behavioral Sciences (Basel, Switzerland)</i> , 2013, 3, 330-347.	2.1	51
78	An fMRI investigation of delay discounting in patients with schizophrenia. <i>Brain and Behavior</i> , 2013, 3, 384-401.	2.2	35
79	Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. <i>Neuropsychopharmacology</i> , 2012, 37, 2635-2642.	5.4	83
80	Neurometabolites in schizophrenia and bipolar disorder – A systematic review and meta-analysis. <i>Psychiatry Research - Neuroimaging</i> , 2012, 203, 111-125.	1.8	179
81	Multimodal analysis of the hippocampus in schizophrenia using proton magnetic resonance spectroscopy and functional magnetic resonance imaging. <i>Schizophrenia Research</i> , 2012, 140, 136-142.	2.0	67
82	Ocular Convergence Deficits in Schizophrenia. <i>Frontiers in Psychiatry</i> , 2012, 3, 86.	2.6	9
83	Antipsychotic Drugs Alter Functional Connectivity between the Medial Frontal Cortex, Hippocampus, and Nucleus Accumbens as Measured by H215O PET. <i>Frontiers in Psychiatry</i> , 2012, 3, 105.	2.6	33
84	Combining 1 h MR spectroscopy and fmri during a prediction error task to evaluate the biochemical and functional properties of the sn/vta in individuals with schizophrenia and normal volunteers. <i>International Clinical Psychopharmacology</i> , 2011, 26, e129.	1.7	0
85	Aberrant visual circuitry associated with normal spatial match-to-sample accuracy in schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2011, 193, 138-143.	1.8	7
86	Mitochondria in the striatum of subjects with schizophrenia: Relationship to treatment response. <i>Synapse</i> , 2011, 65, 215-224.	1.2	27
87	Is there Evidence for Neurotoxicity in the Prodromal and Early Stages of Schizophrenia?. <i>Neuropsychopharmacology</i> , 2011, 36, 1779-1780.	5.4	14
88	Gamma and Delta Neural Oscillations and Association with Clinical Symptoms under Subanesthetic Ketamine. <i>Neuropsychopharmacology</i> , 2010, 35, 632-640.	5.4	238
89	Assessments of Function and Biochemistry of the Anterior Cingulate Cortex in Schizophrenia. <i>Biological Psychiatry</i> , 2010, 68, 625-633.	1.3	115
90	Modulation of Limbic Circuitry Predicts Treatment Response to Antipsychotic Medication: A Functional Imaging Study in Schizophrenia. <i>Neuropsychopharmacology</i> , 2009, 34, 2675-2690.	5.4	94

#	ARTICLE	IF	CITATIONS
91	Dopaminergic synapses in the caudate of subjects with schizophrenia: Relationship to treatment response. <i>Synapse</i> , 2009, 63, 520-530.	1.2	55
92	Correlations Between rCBF and Symptoms in Two Independent Cohorts of Drug-Free Patients with Schizophrenia. <i>Neuropsychopharmacology</i> , 2006, 31, 221-230.	5.4	122
93	Negative Signs and Symptoms Secondary to Antipsychotics: A Double-Blind, Randomized Trial of a Single Dose of Placebo, Haloperidol, and Risperidone in Healthy Volunteers. <i>American Journal of Psychiatry</i> , 2006, 163, 488-493.	7.2	117
94	Functional effects of single dose first- and second-generation antipsychotic administration in subjects with schizophrenia. <i>Psychiatry Research - Neuroimaging</i> , 2005, 139, 19-30.	1.8	66
95	The effects of a subanesthetic dose of ketamine on verbal memory in normal volunteers. <i>Psychopharmacology</i> , 2005, 183, 265-274.	3.1	80
96	Subtle effects of ketamine on memory when administered following stimulus presentation. <i>Psychopharmacology</i> , 2005, 180, 385-390.	3.1	8
97	Effects of Noncompetitive NMDA Receptor Blockade on Anterior Cingulate Cerebral Blood Flow in Volunteers with Schizophrenia. <i>Neuropsychopharmacology</i> , 2005, 30, 2275-2282.	5.4	103
98	Clozapine but not Haloperidol Re-establishes Normal Task-Activated rCBF Patterns in Schizophrenia within the Anterior Cingulate Cortex. <i>Neuropsychopharmacology</i> , 2004, 29, 171-178.	5.4	76
99	Parametric study of accuracy and response time in schizophrenic persons making visual or auditory discriminations. <i>Psychiatry Research</i> , 2004, 127, 207-216.	3.3	6
100	Evaluating Glutamatergic Transmission in Schizophrenia. <i>Annals of the New York Academy of Sciences</i> , 2003, 1003, 113-118.	3.8	48
101	Functional effects of antipsychotic drugs: comparing clozapine with haloperidol. <i>Biological Psychiatry</i> , 2003, 53, 601-608.	1.3	130
102	Schizophrenia, VIII: Pharmacologic Models. <i>American Journal of Psychiatry</i> , 2003, 160, 2091-2091.	7.2	7
103	Effects of Ketamine on Leading Saccades During Smooth-Pursuit Eye Movements May Implicate Cerebellar Dysfunction in Schizophrenia. <i>American Journal of Psychiatry</i> , 2002, 159, 1490-1496.	7.2	50
104	Long-term outcome of patients who receive ketamine during research. <i>Biological Psychiatry</i> , 2001, 49, 869-875.	1.3	47
105	Abnormal Patterns of Regional Cerebral Blood Flow in Schizophrenia With Primary Negative Symptoms During an Effortful Auditory Recognition Task. <i>American Journal of Psychiatry</i> , 2001, 158, 1797-1808.	7.2	101
106	Probing the human hippocampus using rCBF: Contrasts in schizophrenia. <i>Hippocampus</i> , 2001, 11, 543-550.	1.9	233
107	Sequential Regional Cerebral Blood Flow Brain Scans Using PET with H2150 Demonstrate Ketamine Actions in CNS Dynamically. <i>Neuropsychopharmacology</i> , 2001, 25, 165-172.	5.4	137
108	Effects of Ketamine in Normal and Schizophrenic Volunteers. <i>Neuropsychopharmacology</i> , 2001, 25, 455-467.	5.4	576

#	ARTICLE	IF	CITATIONS
109	Brain Activation Patterns in Schizophrenic and Comparison Volunteers During a Matched-Performance Auditory Recognition Task. <i>American Journal of Psychiatry</i> , 2000, 157, 1634-1645.	7.2	58
110	Ketamine Effects on Eye Movements. <i>Neuropsychopharmacology</i> , 2000, 23, 645-653.	5.4	71
111	NMDA-Sensitive Glutamate Antagonism A Human Model for Psychosis. <i>Neuropsychopharmacology</i> , 1999, 21, S158-S169.	5.4	30
112	Antipsychotic Properties of the Partial Dopamine Agonist ( $\hat{\alpha}$ )-3-(3-Hydroxyphenyl)-N-n-Propylpiperidine (Preclamol) in Schizophrenia. <i>Biological Psychiatry</i> , 1998, 43, 2-11.	1.3	105
113	The relationship between smooth pursuit eye movements and tardive dyskinesia in schizophrenia. <i>Schizophrenia Research</i> , 1998, 31, 141-150.	2.0	8
114	Association Between Eye Tracking Disorder in Schizophrenia and Poor Sensory Integration. <i>American Journal of Psychiatry</i> , 1998, 155, 1352-1357.	7.2	25
115	Clinical Genetics, V : Association of Genetic and Personality Characteristics. <i>American Journal of Psychiatry</i> , 1997, 154, 1496-1496.	7.2	3
116	Regional correlations between ketamine-induced actions on psychosis and regional cerebral blood flow (rCBF). <i>Schizophrenia Research</i> , 1997, 24, 167-168.	2.0	2
117	Eye Tracking Disorder in Schizophrenia Is Characterized by Specific Ocular Motor Defects and Is Associated with the Deficit Syndrome. <i>Biological Psychiatry</i> , 1997, 42, 781-796.	1.3	58
118	Does pursuit abnormality in schizophrenia represent a deficit in the predictive mechanism?. <i>Psychiatry Research</i> , 1996, 59, 221-237.	3.3	45
119	Absence of ketamine effects on memory and other cognitive functions in schizophrenic patients. <i>Journal of Psychiatric Research</i> , 1996, 30, 321-330.	3.1	28
120	Ketamine activates psychosis and alters limbic blood flow in schizophrenia. <i>NeuroReport</i> , 1995, 6, 869-872.	1.2	423
121	D2-Family Receptors in Schizophrenia: Distribution and Implications for Treatment. <i>Clinical Neuropharmacology</i> , 1995, 18, S110-S120.	0.7	5
122	Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. <i>Neuropsychopharmacology</i> , 1995, 13, 9-19.	5.4	753
123	Recent developments in the neuropharmacology of schizophrenia. <i>American Journal of Health-System Pharmacy</i> , 1995, 52, S5-S8.	1.0	8
124	Subanesthetic Doses of Ketamine Stimulate Psychosis in Schizophrenia. <i>Neuropsychopharmacology</i> , 1995, 13, 9-19.	5.4	106
125	GABA hypothesis of tardive dyskinesia: clinical neurochemistry and neurophysiology. <i>Schizophrenia Research</i> , 1989, 2, 237.	2.0	0
126	GABA hypothesis of tardive dyskinesia: pharmacology. <i>Schizophrenia Research</i> , 1989, 2, 239.	2.0	0

#	ARTICLE	IF	CITATIONS
127	Regional Decoupling of N-acetyl-aspartate and Glutamate in Schizophrenia. , 0, .		1
128	In vivo Experience With NRT to Increase Adherence and Smoking Abstinence Among Individuals in the Criminal Legal System: Study Protocol for a Randomized Clinical Trial. <i>Frontiers in Psychiatry</i> , 0, 13, .	2.6	1